Trials / Unknown
UnknownNCT01216826
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sidnei Epelman · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma. The aim response is defined as complete or partial response (according to RECIST criteria) for at least 4 weeks, or stable disease for at least 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus | Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity. |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2014-06-01
- Completion
- 2014-12-01
- First posted
- 2010-10-07
- Last updated
- 2013-08-07
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01216826. Inclusion in this directory is not an endorsement.